Literature DB >> 29900998

Beta-2 Microglobulin in Whole Unstimulated Saliva Can Effectively Distinguish Between Sjögren's Syndrome and Non-Autoimmune Sicca Symptoms.

Janett Riega-Torres1, Guillermo Delgado-García2, Julio César Salas-Alanís3, Cassandra Skinner-Taylor1, Lorena Pérez-Barbosa1, Mario Garza-Elizondo1, Celia Nohemí Sánchez-Domínguez4, Luis Ángel Ceceñas-Falcón5, Karim Mohamed-Noriega6, Jesús Mohamed-Hamsho6, David Vega-Morales1.   

Abstract

OBJECTIVES: This study aims to describe salivary beta-2 microglobulin (sB2M) levels in our setting and to assess the performance of sB2M for the diagnosis of Sjögren's syndrome (SS). PATIENTS AND METHODS: This cross-sectional, comparative study included 192 SS patients (2 males, 190 females; mean age 53.1 years; range 23 to 84 years) and 64 healthy controls (1 male, 63 females; mean age 46.9 years; range 21 to 82 years). Patients were divided into three groups as those with primary SS, secondary SS, and sicca non-Sjögren's syndrome (snSS). sB2M was measured by enzyme-linked immunosorbent assay in whole unstimulated saliva (ng/mL). Differences in sB2M were evaluated using the Kruskal-Wallis test. Receiver operating curves were generated to determine the performance of sB2M for distinguishing between SS and non-autoimmune snSS groups, and between SS group and healthy controls.
RESULTS: The primary SS and secondary SS groups had a significantly higher concentration of sB2M than the other two groups. There was no significant difference in the concentration of sB2M between primary SS and secondary SS groups, and neither between snSS group and healthy controls. The receiver operating curve analysis for distinguishing SS and snSS showed an area under the curve of 0.661 (95% confidence interval 0.590-0.728, p=0.0001) with an optimal cutoff value of 0.582 ng/mL. Sensitivity, specificity, positive predictive value, and negative predictive value were 68.7%, 59.3%, 20.2%, and 92.7%, respectively. The reported prevalence of SS in Mexico was considered when calculating the last two values.
CONCLUSION: In our setting, sB2M effectively distinguished between SS patients and non-autoimmune sicca symptoms. Including sB2M in our conventional diagnostic arsenal may assist in the evaluation of patients in whom SS is suspected; however, further studies are needed to clarify this hypothesis.

Entities:  

Keywords:  Beta-2 microglobulin; Sjögren’s syndrome; diagnosis; saliva

Year:  2017        PMID: 29900998      PMCID: PMC5868470          DOI: 10.5606/ArchRheumatol.2017.6273

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  20 in total

1.  Prevalence of Sjögren's syndrome in ambulatory patients according to the American-European Consensus Group criteria.

Authors:  J Sánchez-Guerrero; M R Pérez-Dosal; F Cárdenas-Velázquez; A Pérez-Reguera; E Celis-Aguilar; A E Soto-Rojas; C Avila-Casado
Journal:  Rheumatology (Oxford)       Date:  2004-10-27       Impact factor: 7.580

2.  Diagnostic significance of salivary levels of beta 2-microglobulin in Sjögren's syndrome.

Authors:  A J Swaak; L L Visch; A Zonneveld
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

3.  Salivary β2-microglobulin positively correlates with ESSPRI in patients with primary Sjögren's syndrome.

Authors:  Felipe Garza-García; Guillermo Delgado-García; Mario Garza-Elizondo; Luis Ángel Ceceñas-Falcón; Dionicio Galarza-Delgado; Janett Riega-Torres
Journal:  Rev Bras Reumatol Engl Ed       Date:  2016-12-14

4.  Cut-off levels of salivary beta2-microglobulin and sodium differentiating patients with Sjögren's syndrome from those without it and healthy controls.

Authors:  Hiromitsu Asashima; Shigeko Inokuma; Masahito Onoda; Masae Oritsu
Journal:  Clin Exp Rheumatol       Date:  2013-06-26       Impact factor: 4.473

5.  Beta 2 microglobulin measurements in saliva of patients with primary Sjögren's syndrome: influence of flow.

Authors:  S A van der Geest; H M Markusse; A J Swaak
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

6.  Salivary and serum beta2-microglobulin and gamma-glutamyl-transferase in patients with primary Sjögren syndrome and Sjögren syndrome secondary to systemic lupus erythematosus.

Authors:  José Castro; Juan Jiménez-Alonso; José Mario Sabio; Francisco Rivera-Cívico; María Martín-Armada; Miguel Angel Rodríguez; Laura Jáimez; María Jesús Castillo; Julio Sánchez-Román
Journal:  Clin Chim Acta       Date:  2003-08       Impact factor: 3.786

7.  Elevated salivary and synovial fluid beta2-microglobulin in Sjogren's syndrome and rheumatoid arthritis.

Authors:  N Talal; H M Grey; N Zvaifler; J P Michalski; T E Daniels
Journal:  Science       Date:  1975-03-28       Impact factor: 47.728

8.  The diagnostic value of salivary fluid levels of beta 2-microglobulin, lysozyme and lactoferrin for primary Sjögren's syndrome.

Authors:  H M Markusse; H G Otten; T M Vroom; T J Smeets; N Fokkens; F C Breedveld
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

9.  The diagnosis value of beta 2-microglobulin and immunoglobulins in primary Sjögren's syndrome.

Authors:  S Maddali Bongi; G Campana; A D'Agata; C Palermo; G Bianucci
Journal:  Clin Rheumatol       Date:  1995-03       Impact factor: 2.980

10.  Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes.

Authors:  Chiara Baldini; Laura Giusti; Federica Ciregia; Ylenia Da Valle; Camillo Giacomelli; Elena Donadio; Francesca Sernissi; Laura Bazzichi; Gino Giannaccini; Stefano Bombardieri; Antonio Lucacchini
Journal:  Arthritis Res Ther       Date:  2011-11-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.